Gefitinib-Related Interstitial Pneumonia / 결핵및호흡기질환
Tuberculosis and Respiratory Diseases
; : 134-139, 2007.
Article
in Ko
| WPRIM
| ID: wpr-122251
Responsible library:
WPRO
ABSTRACT
Gefitinib is a novel drug used to treat advanced non-small cell lung cancer. However, drug-related interstitial pneumonia is a major life-threatening side effect, which has a worldwide prevalence of 0.3-0.4%. In Japan, the prevalence is high as 3-4% but the actual frequency in Korea has not been officially assessed. We report two cases of gefitinib-induced interstitial lung disease during the treatment of non-small cell lung cancer. High-resolution computerized tomography (HRCT) of one case showed nonspecific ground glass opacity and the chest x-ray of another case showed diffuse bilateral ground glass opacity. The former patient showed a rapid good response to corticosteroid treatment whereas the latter died despite receiving aggressive treatment with high dose corticosteroid and empirical antibiotics.
Key words
Full text:
1
Index:
WPRIM
Main subject:
Thorax
/
Prevalence
/
Lung Diseases, Interstitial
/
Carcinoma, Non-Small-Cell Lung
/
Glass
/
Japan
/
Korea
/
Anti-Bacterial Agents
Type of study:
Prevalence_studies
Limits:
Humans
Country/Region as subject:
Asia
Language:
Ko
Journal:
Tuberculosis and Respiratory Diseases
Year:
2007
Type:
Article